NB-02 / Dong-A - LARVOL DELTA

Novel botanical therapeutic NB-02 effectively treats Alzheimer's neuropathophysiology in an APP/PS1 mouse model. (PubMed, eNeuro) - "It normalizes neuronal calcium homeostasis, thus restoring neuronal function, and upregulates neuroinflammation. Since NB-02 was effective in slowing pathophysiology in an animal model of amyloidosis, it holds great promise as a therapeutic approach to treat Alzheimer's disease."

Journal • Preclinical • Alzheimer's Disease • Amyloidosis • CNS Disorders • Dementia • Immunology • Inflammation

NeuroBo Pharmaceuticals reports first quarter 2020 financial results (PRNewswire) - "Subject to improvement of global health and macroeconomic conditions, we plan to submit an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for NB-02 and to initiate a Phase 1 trial in the first quarter of next year."

IND • New P1 trial • Alzheimer's Disease • CNS Disorders

NeuroBo pharmaceuticals announces issuance of U.S. patent, providing broad coverage of NB-02 for neurodegenerative disorders (PRNewswire) - "NeuroBo Pharmaceuticals, Inc....today announced that on March 17, 2020 the United States Patent and Trademark Office issued Patent No. 10,588,927 B2...'This additional composition patent validates our position that NB-02, in development for Alzheimer's disease and other dementias, may be useful as a pharmaceutical for preventing or treating degenerative neurological diseases'....'Our recently announced $7.5 million financing, when combined with current cash on hand, will allow us to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for NB-02 and to initiate a Phase 1 trial when global health and macroeconomic conditions improve.'"

Financing • IND • New P1 trial • Patent • Alzheimer's Disease • CNS Disorders • Tauopathies And Synucleinopathies